December 2013

 

In this Supplement

Innovating For Clinical Performance

Valiant® Mona LSA Stent Graft Selected by the FDA for an early feasibility pilot program

Issue

Supplement

Download a PDF of this supplement

From Benchtop to Bedside With the Valiant Mona LSA Thoracic Stent Graft

How physicians, engineers, and regulatory agencies can work together to best serve patients with new technologies.

By Frank R. Arko, III, MD

Branch Technology: Innovation in the Development Process

Increasing AAA and TAA patient applicability while ensuring quality from design to market.

By Peter Larson, MS, BS; Emilie Simmons, MS; and Paige Bota, BS, PhD

Why Evidence Matters in Innovation

The importance of clinical evidence in today’s medical practice.

By Kenneth Ouriel, MD, MBA

Empowering EVAR Clinical Performance

Endurant II Stent Graft Durable Outcomes in the ENGAGE Real-World Registry

By Pieter P.H.L. Broos, MD; Philippe W.M. Cuypers, MD, PhD; Joep A.W. Teijink, MD, PhD; and Marc R.H.M. van Sambeek, MD, PhD

Consistent Durable Outcomes At 3-Year Follow-Up Across Endurant Trials*

Empowering EVAR clinical performance.

By Sharif H. Ellozy, MD

Addressing Challenging AAA Anatomies With Confidence

Hence J.M. Verhagen, MD, PhD, discusses how the Endurant II Stent Graft has performed well in challenging anatomy, enabling physicians to successfully treat a broader range of AAA patients.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.